RITZ-5: Randomized intravenous tezosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: A prospective, multicenter, double-blind, placebo-controlled study

Journal of the American College of Cardiology

Volumn 41, Issue 2, 2003, Pages 204-210

  Kaluski, Edo ^a   Kobrin, Isaac ^d   Zimlichman, Reuven ^b   Marmor, Alon ^e   Krakov, Oscar ^c   Milo, Olga ^a   Frey, Aline ^d   Kaplan, Shoshana ^a   Krakover, Rikardo ^a   Caspi, Avi ^d   Vered, Zvi ^a   Cotter, Gad ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c KAPLAN MEDICAL CENTER   (Israel)

^d ACTELION PHARMACEUTICALS LTD   (Switzerland)

^e Assaf Harofeh Medical Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; FUROSEMIDE; ISOSORBIDE DINITRATE; MORPHINE; TEZOSENTAN;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HEART EJECTION FRACTION; HEART INFARCTION; HUMAN; INCIDENCE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; OXYGEN SATURATION; OXYGEN THERAPY; PRIORITY JOURNAL; PULSE OXIMETER; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESPIRATORY FAILURE; TREATMENT OUTCOME; VASODILATATION;

DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; INJECTIONS, INTRAVENOUS; PROSPECTIVE STUDIES; PULMONARY EDEMA; PYRIDINES; RECEPTORS, ENDOTHELIN; TETRAZOLES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0037438919     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02708-0     Document Type: Article

References (19)

1. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-93.
2. Sharon A, Shpirer I, Kaluski E, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 2000;36:832-7.
3. Cotter G, Moshkovitz Y, Milovanov O, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Failure 2002;4:227-34.
4. Cotter G, Moshkovitz Y, Kaluski E, et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure (abstr). Eur Heart J 2002;23 Suppl:172.
5. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
6. Kiowski W, Kiowski W, Sutsch G, et al. Evidence of endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-6.
7. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 1992;85:1374-9.
8. Pacher R, Stanek B, Hulsman M, et al. Prognostic impact of big endothelin-1 plasma concentrations, compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-41.
9. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89:1580-6.
10. Torte Amione G, Young JB, Durand J, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001;103:973-80.
11. Cotter G, Kiowski W, Kaluski E, Tezosentan reduces peripheral resistance and increases myocardial contractility, despite reducing left ventricular (wedge) pressure in patients with congestive heart failure (abstr). Eur Heart J 2000;21 Suppl: 295.
12. Cotter G, Faibel H, Barash P, et al. High-dose nitrates in the immediate management of unstable angina: optimal dosage, route of administration, and therapeutic goals. J Emerg Med 1998;16:219-24.
13. Cotter G, Kaluski E, Moshkovitz Y, Milovanov O, Krakover R, Vered Z. Pulmonary edema: new insight on pathogenesis and treatment. Curr Opin Cardiol 2001;16:159-63.
14. Teerlink JR, Massie BM, Cleland JG, Tzivoni D, for the RITZ-1 Investigators. A double-blind, parallel-group, multi-center, placebo-controlled study to investigate the efficacy and safety of tezosentan in reducing symptoms in patients with acute decompensated heart failure (RITZ-1) (abstr). Circulation 2001;104:II526.
15. VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. A randomized trial. JAMA 2002;287:1531-40.
16. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
17. Qiu C, Ding SS, Hess P, Clozel JP, Clozel M. Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure. J Cardiovasc Pharmacol 2001;38:317-24.
18. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-23.
19. Packer M. Effects of the endothelin receptor antagonist bosentan on the morbidity and mortality in patients with chronic heart failure. Results of the ENABLE 1 and 2 trial program. Congr of the Am Coll of Cardiol 2002;Late Breaking Clinical Trials:Special Topic #412.